Literature DB >> 34272593

Identification of mouse helper epitopes for WT1-specific CD4+ T cells.

Hiroko Nakajima1, Jun Nakata2, Kanako Imafuku2, Hiromu Hayashibara2, Kazuki Isokawa2, Keiko Udaka3, Fumihiro Fujiki4, Soyoko Morimoto5, Kana Hasegawa4, Naoki Hosen6, Yoshiko Hashii5, Sumiyuki Nishida7, Akihiro Tsuboi5, Yoshihiro Oka7,8,9, Yusuke Oji2, Shinji Sogo4,10, Haruo Sugiyama4.   

Abstract

Helper T lymphocytes (HTLs) play a central role in cancer immunity because they can not only help the induction and proliferation of cytotoxic T lymphocytes (CTLs) but also their differentiation into cytotoxic CD4+ T cells and directly kill the target cells.This study describes the identification of three novel mouse Th epitope peptides, WT135-52, WT186-102 and WT1294-312, derived from WT1 protein, which is the most potent tumor-associated antigen. Compared to immunization with WT1 CTL peptide alone, immunization with the addition of these WT1-specific Th peptides strongly induced WT1-specific CTLs, continued to maintain them, and efficiently rejected the challenge of WT1-expressing tumor cells. Importantly, the majority of WT1-specific CTLs induced by the co-immunization with WT1 CTL and the WT1-specific Th peptides were CD44+CD62L- effector memory CD8+ T cells, which played a central role in tumor rejection. Establishment of mouse models suitable for the analysis of the detailed mechanism of these functions of HTLs is very important. These results clearly showed that WT1-specific HTLs perform an essential function in WT1-specific tumor immunity. Therefore, the WT1-specific Th peptides identified here should make a major contribution to elucidation of the mutual roles of WT1-specific CTLs and HTLs in cancer immunity in in vivo mouse models.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CTL; HTL; Helper peptide; Peptide vaccine; WT1

Year:  2021        PMID: 34272593     DOI: 10.1007/s00262-021-03003-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  42 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.

Authors:  Tanyarat Jomgeow; Yusuke Oji; Naoko Tsuji; Yoko Ikeda; Ken Ito; Asako Tsuda; Tsutomu Nakazawa; Naoya Tatsumi; Nao Sakaguchi; Satoshi Takashima; Toshiaki Shirakata; Sumiyuki Nishida; Naoki Hosen; Manabu Kawakami; Akihiro Tsuboi; Yoshihiro Oka; Kazuyuki Itoh; Haruo Sugiyama
Journal:  Cancer Sci       Date:  2006-04       Impact factor: 6.716

3.  Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway.

Authors:  K Ito; Y Oji; N Tatsumi; S Shimizu; Y Kanai; T Nakazawa; M Asada; T Jomgeow; S Aoyagi; Y Nakano; H Tamaki; N Sakaguchi; T Shirakata; S Nishida; M Kawakami; A Tsuboi; Y Oka; Y Tsujimoto; H Sugiyama
Journal:  Oncogene       Date:  2006-03-06       Impact factor: 9.867

Review 4.  WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.

Authors:  Haruo Sugiyama
Journal:  Jpn J Clin Oncol       Date:  2010-04-15       Impact factor: 3.019

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 6.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

7.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Tetsuya Taguchi; Tadashi Osaki; Taiichi Kyo; Hiroko Nakajima; Olga A Elisseeva; Yusuke Oji; Manabu Kawakami; Kazuhiro Ikegame; Naoki Hosen; Satoshi Yoshihara; Fei Wu; Fumihiro Fujiki; Masaki Murakami; Tomoki Masuda; Sumiyuki Nishida; Toshiaki Shirakata; Shin-Ichi Nakatsuka; Ayako Sasaki; Keiko Udaka; Hiroo Dohy; Katsuyuki Aozasa; Shinzaburo Noguchi; Ichiro Kawase; Haruo Sugiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.

Authors:  Akihiro Tsuboi; Yoshihiro Oka; Tadashi Osaki; Toru Kumagai; Isao Tachibana; Seiji Hayashi; Masaki Murakami; Hiroko Nakajima; Olga A Elisseeva; Wu Fei; Tomoki Masuda; Masaki Yasukawa; Yusuke Oji; Manabu Kawakami; Naoki Hosen; Kazuhiro Ikegame; Satoshi Yoshihara; Keiko Udaka; Shin-Ichi Nakatsuka; Katsuyuki Aozasa; Ichiro Kawase; Haruo Sugiyama
Journal:  Microbiol Immunol       Date:  2004       Impact factor: 1.955

10.  The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Authors:  Martin A Cheever; James P Allison; Andrea S Ferris; Olivera J Finn; Benjamin M Hastings; Toby T Hecht; Ira Mellman; Sheila A Prindiville; Jaye L Viner; Louis M Weiner; Lynn M Matrisian
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.